LIMITED OFFER
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code needed.
Nitric Oxide in Health and Disease
Therapeutic Applications in Cancer and Inflammatory Disorders
- 1st Edition - April 13, 2023
- Editors: Lucia Morbidelli, Benjamin Bonavida, Jordi Muntané
- Language: English
- Paperback ISBN:9 7 8 - 0 - 4 4 3 - 1 3 3 4 2 - 8
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 1 3 3 4 3 - 5
Approx.326… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteApprox.326 pages
- Provides updated reviews on the chemistry and signaling of newly derived therapeutic nitric oxide (NO) donors/inhibitors and their complexes in liposomes or nanospheres in both pre-clinical and clinical activities
- Discusses the application of NO in monotherapy or in combination with conventional therapies in a variety of cancers and inflammatory diseases
- Encompasses real-world examples of recent research related to NO and cancer
Graduate students and researchers in cancer research Medical doctors, oncologists
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- About the Editors
- Preface
- References
- Highlights of the II international conference “therapeutic applications of nitric oxide in cancer and inflammatory-related diseases”
- Conference Program
- Part I: Development of NO donors and derivatives, and new delivery formations
- Chapter 1: Nitric oxide and derivatives: Molecular insights and translational opportunities
- Abstract
- Conflict of interest
- Introduction
- Bioavailability/biotransformation of NO
- Role of NO in regulating inflammation and other functions during normal physiological activities
- Role of NO during inflammatory diseases, tumor microenvironment, and cancers progression
- Current clinical trials of NO
- Ying and Yang of nitric oxide studies: Immunosuppressive tumor microenvironment induced by the nitric oxide production
- Conclusion
- References
- Chapter 2: Biomedical applications of polymeric nitric oxide (NO) donors
- Abstract
- Acknowledgment
- Conflict of interest
- Introduction
- Nitric oxide detection
- NO production in human body
- NO-releasing small molecules
- Polymeric NO donors
- Biomedical applications
- Conclusion and future perspectives
- References
- Part II: Nitric oxide pathway and cancer progression and therapy
- Chapter 3: Therapeutic potential for coxib-nitric oxide releasing hybrids in cancer treatment
- Abstract
- Conflict of interest
- Introduction
- COX-2 and cancer
- Hybrid drugs: NO-releasing COX inhibitors
- NO-coxibs based on diarylpyrrole scaffold
- Conclusions
- References
- Chapter 4: Targeting dimethylarginine dimethylaminohydrolase 1 to suppress vasculogenic mimicry in breast cancer: Current evidence and future directions
- Abstract
- Conflict of interest
- Introduction
- Vasculogenic mimicry: Molecular mechanisms and pathophysiological significance
- Dimethylarginine dimethylaminohydrolase 1: Biology and role in vasculogenic mimicry
- Effects of pharmacological DDAH1 inhibition on vasculogenic mimicry in TNBC
- General considerations
- References
- Chapter 5: Cancer stem cells and nitric oxide
- Abstract
- Acknowledgments
- Conflict of interest
- Introduction
- Cancer stem cells
- Nitric oxide
- Nitric oxide as a modulator of the tumor microenvironment
- Expression of nitric oxide synthases in tumors
- Studies concerning CSCs and NO
- NO as a novel therapeutic target in cancer
- Conclusion
- References
- Chapter 6: Inducible nitric oxide synthase 2 (NOS2) and antitumor γδ-T cells
- Abstract
- Acknowledgments
- Conflict of interest
- Introduction
- Cancer immunotherapies
- Gamma delta T (γδ-T) cells
- INOS/NOS2 expression
- NOS2 and γδ-T cells
- γδ-T cells in cancer immunotherapy
- Perspectives
- References
- Chapter 7: The regulation of the programmed death ligand 1 (PD-L1) by nitric oxide in breast cancer: Immunotherapeutic implication
- Abstract
- Acknowledgments
- Conflict of interest
- Introduction
- Evasion of cancer cells from CD8 T-cell–mediated immunotherapy: Role of PD-L1/PD-1 interactions
- Programmed death ligand 1
- Reversal of resistance to CMI by checkpoint inhibitors
- Regulation of PD-L1 expression on cancer cells
- Regulation of PD-L1 expression by nitric oxide (NO)
- Inhibitors of NO and inhibition of PD-L1: Restoration of cancer cell response to CD8 T-cell–mediated immunotherapy
- Remarks and perspectives
- References
- Chapter 8: Pepper fruit, as a nutraceutical food, shows antiproliferative activity against tumor cells and it is potentiatied by nitric oxide (NO)
- Abstract
- Conflict of interest
- Acknowledgments
- Introduction
- Pepper fruit as a potential source of antitumoral compounds
- Ripening and NO boost the nutritional properties of pepper fruits
- Pepper fruits show antiproliferative activity on tumor cells
- Conclusions
- References
- Part III: Nitric oxide donors and cardiovascular and metabolic diseases
- Chapter 9: Nitric oxide (NO) donors in kidney damage and diseases
- Abstract
- Conflict of interest
- Acknowledgments
- Introduction
- Physiological role of nitric oxide in the kidneys
- Applicability and limitations of NO donors
- Conclusions
- References
- Chapter 10: Nitric oxide resistance in type 2 diabetes: Potential implications of HNO donors
- Abstract
- Acknowledgments
- Conflict of interest
- Introduction
- Evidence of NO• resistance in T2DM
- Nitroxyl (HNO)
- HNO donation, Angeli’s salt, and NO• resistance in T2DM
- Conclusion and perspectives
- References
- Chapter 11: Inhaled nitric oxide (iNO) administration in intubated and nonintubated patients: Delivery systems, interfaces, dose administration, and monitoring techniques
- Abstract
- Conflict of interest
- Inhaled nitric oxide in intubated patients
- Inhaled nitric oxide in nonintubated patients
- Inhaled nitric oxide administration in clinical practice
- References
- Chapter 12: Inhaled nitric oxide (iNO): Clinical applications in critical care medicine, delivery devices, and measuring techniques
- Abstract
- Conflict of interest
- Introduction
- NO sources
- References
- Chapter 13: Mechanistic insights on the role of nitric oxide in ischemia-reperfusion injury
- Abstract
- Conflict of interest
- Introduction
- Nitric oxide derivatives
- Nitric oxide pathophysiology in ischemic reperfusion injury
- Signaling pathways mediated by nitric oxide involved in ischemia-reperfusion injury
- Conclusion
- References
- Part IV: Nitric oxide derivatives in ocular diseases
- Chapter 14: Effect of nitric oxide inhibitors in retinitis pigmentosa
- Abstract
- Acknowledgments
- Conflict of interest
- Nitric oxide (NO) in the retina
- Retinitis pigmentosa
- Nitric oxide inhibitors
- Nitric oxide inhibitors in retinitis pigmentosa
- Conclusion
- References
- Chapter 15: Advances in the discovery of novel agents for the treatment of glaucoma: The role of nitric oxide donors
- Abstract
- Conflict of interest
- Introduction
- Carbonic anhydrase inhibitors as antiglaucoma agents
- Carbonic anhydrase inhibitor: NO donor hybrids
- Prostaglandin receptor agonists as antiglaucoma agents
- PG agonists: NO donor hybrids
- Nitric oxide donors per se
- Conclusions
- References
- Conclusions and future perspectives
- References
- Index
- No. of pages: 364
- Language: English
- Edition: 1
- Published: April 13, 2023
- Imprint: Academic Press
- Paperback ISBN: 9780443133428
- eBook ISBN: 9780443133435
LM
Lucia Morbidelli
Dr. Morbidelli’s experience is within the molecular and biochemical pharmacology of angiogenesis and microcirculation and its biological application in diseases and cancer. Through of a plethora of in vitro and in vivo models, she has contributed to the characterization of the pro- and antiangiogenic activities of designed synthetic molecules and natural products and their potential applications in angiogenesis-dependent diseases of the cardiovascular system, ocular disorders, neurovascular diseases and cancer. She co-organized with Professor Bonavida the Fourth International Workshop on “Nitric Oxide in Cancer” held in Sevilla in March 13-14, 2015. The meeting addressed different topics such as NO, mutagenesis, carcinogenesis, tumor promotion and tumor growth; NO regulation of cell death pathways; NO and proliferation and epithelial-mesenchymal transition; Regulation of immune response by NO; Antitumoral activity of NO-based releasing strategies: pre-clinical studies; Antitumoral activity of NO-based releasing strategies: clinical trials.
Affiliations and expertise
Professor, Department of Life Sciences, University of Siena, Siena, ItalyBB
Benjamin Bonavida
Dr. Benjamin Bonavida is currently a Distinguished Research Professor at the University of California, Los Angeles (UCLA). He is affiliated with the Department of Microbiology, Immunology and Molecular Genetics, UCLA David Geffen School of Medicine, and the Jonsson Comprehensive Cancer Center at UCLA. His research career, thus far, has focused on investigations in the fields of basic immunochemistry and cancer immunobiology. His research investigations have ranged from the biochemical, molecular, and genetic mechanisms of cell-mediated killing and tumor cell resistance to chemo-immuno cytotoxic drugs. The reversal of tumor cell resistance was investigated by the use of various selected sensitizing agents based on molecular mechanisms of resistance. In these investigations, there was the newly characterized dysregulated NF-kB/ Snail/YY1/RKIP/PTEN loop in many cancers that was reported to regulate cell survival, proliferation, invasion, metastasis, and resistance. Emphasis was focused on the roles of the tumor suppressor Raf kinase inhibitor protein (RKIP) and the tumor promoter Yin Yang 1 (YY1) and the role of nitric oxide (NO) as a chemo-immuno-sensitizing factor. Many of the aforementioned studies are centered on the clinical challenging features of cancer patients’ failure to respond to both conventional and targeted therapies.
Dr. Bonavida has been active in the organization of regular sequential international miniconferences that are highly focused on the roles of YY1, RKIP, and nitric oxide in cancer and their potential therapeutic applications. Several books edited or coedited have been published. In addition, he is the Series Editor of books (over 20) published by Springer/Nature: Resistance to Anti-Cancer Targeted Therapeutics. In addition, he is presently the Series Editor of Three Series published by Elsevier/Academic Press on “Cancer Sensitizing Agents for Chemotherapy,” “Sensitizing Agents for Cancer Resistance to Cell Mediated Immunotherapy,” and “Breaking Tolerance to Anti-Cancer Antibody Immunotherapy.” He is the Editor-in-Chief of the Journal Critical Reviews in Oncogenesis, Editor-in-Chief of Onco Therapeutics, and Associate Editor of “Critical Reviews in Immunology.” Dr. Bonavida has published over 500 research publications and reviews in various scientific journals of high impact.
Affiliations and expertise
Distinguished Research Professor, Department of Microbiology, Immunology and Molecular Genetics, David Ge en School of Medicine, Jonsson Comprehensive Cancer Center, University of California at Los Angeles, California, USAJM
Jordi Muntané
Dr. Muntané’s scientific career has been all devoted to the study of the relevance of oxidative and nitrosative stress in cell proliferation and death in different experimental models and clinical settings such as acute hepatocellular injury and hepatocarcinoma. The relevance of the temporal, dose and compartmentalization of nitric oxide (NO) release has been related to cytotoxicity, as well as the cytoprotective properties of classical antioxidants, prostanoids and alpha-tocopherol in different experimental models of liver injury. The anti-tumoral properties of NO has also been demonstrated using NO-donors and nitric oxide synthase type III (NOS3) overexpression in in vivo and in vitro models. The involvement of NO in the antitumoral properties of the molecular recommended therapies for patients with advanced hepatocarcinoma, such as the tyrosine kinase inhibitor Sorafenib, has also been studied comprehensively by Dr. Muntané’s lab.
Affiliations and expertise
Dept Medical Physiology and Biophysics, Institute of Biomedicine of Seville (IBiS), SpainRead Nitric Oxide in Health and Disease on ScienceDirect